Navigation Links
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
Date:1/12/2009

been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.

About Green Cross Corporation

Green Cross is a leader in the Korean biotechnology and pharmaceutical industries. Green Cro
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
2. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
3. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
6. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
10. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... DIEGO , Dec. 24, 2014  Conkwest, ... West, developing the proprietary Natural Killer (NK) cell-line ... that Dr. Patrick Soon-Shiong , NantWorks founder, ... a definitive agreement to purchase approximately $48 million ... connection with the investment, he will be named ...
(Date:12/24/2014)... Wis. , Dec. 23, 2014 PuraMed ... marketer of over-the-counter (OTC) medicinal and healthcare products, announced ... of MigraPure® H, a hemp-based, advanced headache relief product, ... dispensaries in Colorado , ... . With the MigraPure H Advanced headache ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... 1, 2011 Takeda Global Research & ... and Drug Administration (FDA) has assigned a Prescription Drug ... 2012 for the review of its investigational type 2 ... which combines alogliptin with pioglitazone in a single tablet. ...
... Medela will host its third annual Human Milk (breast ... National Prematurity Awareness Month. As part of the campaign, Medela ... to neonatal intensive care units across the country. ... awareness of the importance of human milk feeding -- to ...
Cached Medicine Technology:Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 2Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 3Medela Announces Virtual Breast Milk Collection Campaign in Honor of Prematurity Awareness Month 2
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
(Date:12/25/2014)... December 25, 2014 Parker & Sons, ... customer service and affordable quality regarding heating, cooling and ... recognition in 2014 by the “Queen of Clean” for ... earned an impressive reputation over the years for providing ... wide range of contractor services for both homeowners and ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... , California emergency departments first ... FRANCISCO, June 29 CalRHIO announced today that it has ... California to measure savings resulting from physicians having secure ... Information Exchange (HIE). The first phase of the initiative will ...
... Carolinas HealthCare System has organized ... of cardiovascular services in North and South Carolina. , ... Vascular Institute (SHVI) represents a combination of Sanger ... The Institute will continue serving as a regional referral center ...
... $60 Million Medicaid Funding Boost Merely Scratches Surface in Terms ... June 29 In summing up the 2009 session of ... session called by Governor Rick Perry, the Texas Health Care ... rate increase ($60 million general revenue) for Medicaid-financed nursing home ...
... researchers find supportive parents help keep abusive behaviors at bay ... life miserable for plenty of students, only these days some ... that many children in grades 6 through 10 have either ... through cell phones. , The study by the National Institutes ...
... ... on Drug Abuse (VIDA) working in collaboration with colleagues at Vector Tobacco, Inc. and Duke ... better chance at kicking the tobacco habit. , ... Manhasset, NY (Vocus) June 29, 2009 -- Scientists at the ...
... JACKSONVILLE, Fla., June 29 On June 26, 2009 ... Association for the Study of Diabetes investigated the possible ... the development of certain malignancies. The authors themselves, and ... data and analyses, which precluded them from drawing any ...
Cached Medicine News:Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 2Health News:CalRHIO Selects RAND-USC to Evaluate Savings Resulting from Use of Statewide Health Information Exchange 3Health News:Sanger Clinic Lends Its Name to New Heart Care Institute Serving NC and SC 2Health News:THCA on 2009 Legislative Session: Seniors' Medicaid-Financed Nursing Home Care Requires Substantially More Investment as Population Ages, Care Needs Grow 2Health News:Cyber Bullying Affects One in 10 Students 2Health News:Cyber Bullying Affects One in 10 Students 3Health News:News from the Latest Issue of Molecular Medicine Kicking The Habit - It's In The Genes 2Health News:AACE Response to Insulin Glargine Cancer Risk Articles in Diabetologia 2
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Mentor Freedom Pak Seven Starter ... week's supply of Freedom Clear ... all 100% latex-free ... for your convenience and comfort. ...
Medicine Products: